for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

T2 Biosystems Inc

TTOO.OQ

Latest Trade

1.30USD

Change

0.00(0.00%)

Volume

698,851

Today's Range

1.22

 - 

1.32

52 Week Range

0.48

 - 

3.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

T2 Biosystems Reports Q4 Loss Per Share of $0.07

March 4 (Reuters) - T2 Biosystems Inc <TTOO.O>::Q4 LOSS PER SHARE $0.07.Q4 REVENUE $7.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $8.1 MILLION.SEES FY REVENUE $24 MILLION TO $26 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES DATA.

T2 Biosystems Inc Says Entered Into Amendment No.6 To Term Loan Agreement With CRG Servicing Llc On Jan. 25

Jan 27 (Reuters) - T2 Biosystems Inc <TTOO.O>::T2 BIOSYSTEMS INC - ON JAN 25, ENTERED INTO AMENDMENT NO. 6 TO TERM LOAN AGREEMENT WITH CRG SERVICING LLC.T2 BIOSYSTEMS INC - SIXTH AMENDMENT EXTENDS INTEREST-ONLY PAYMENT PERIOD FROM DECEMBER 31, 2021 TO DECEMBER 31, 2022.T2 BIOSYSTEMS INC - SIXTH AMENDMENT REDUCES ANNUAL PRODUCT REVENUE TARGET FOR TWENTY-FOUR MONTH PERIOD BEGINNING ON JANUARY 1, 2020.

T2 Biosystems Sees Q4 2020 Revenue $7.8 million

Jan 26 (Reuters) - T2 Biosystems Inc <TTOO.O>::T2 BIOSYSTEMS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2020 RESULTS.SEES Q4 2020 REVENUE $7.8 MILLION.SEES FY 2020 REVENUE $18.1 MILLION.Q4 REVENUE VIEW $9.0 MILLION -- REFINITIV IBES DATA.

T2 Biosystems Announces Third Quarter 2020 Financial Results

Nov 4 (Reuters) - T2 Biosystems Inc <TTOO.O>::T2 BIOSYSTEMS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.08.Q3 REVENUE $5.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $5.1 MILLION.SEES Q4 2020 REVENUE $8.7 MILLION TO $9.7 MILLION.SEES FY 2020 REVENUE $19 MILLION TO $20 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.

T2 Biosystems Reports Q2 Loss Per Share $0.09

Aug 11 (Reuters) - T2 Biosystems Inc <TTOO.O>::T2 BIOSYSTEMS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.09.SEES FY 2020 REVENUE $18 MILLION TO $20 MILLION.Q2 REVENUE $2.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $2.4 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.15 -- REFINITIV IBES DATA.FY2020 REVENUE VIEW $14.6 MILLION -- REFINITIV IBES DATA.

T2 Biosystems Sees Q2 2020 Revenue $2.4 Million To $2.6 Million

June 30 (Reuters) - T2 Biosystems Inc <TTOO.O>::T2 BIOSYSTEMS ANNOUNCES PRELIMINARY SECOND QUARTER 2020 FINANCIAL RESULTS.SEES Q2 2020 REVENUE $2.4 MILLION TO $2.6 MILLION.T2 BIOSYSTEMS - CASH, EQUIVALENTS AS OF JUNE 30, 2020 EXPECTED TO BE ABOUT $36.5 MILLION.

T2 Biosystems Says Regained Compliance With Nasdaq Listing Rule

June 17 (Reuters) - T2 Biosystems Inc <TTOO.O>::T2 BIOSYSTEMS - RECEIVED WRITTEN NOTICE FROM NASDAQ NOTIFYING CO HAD REGAINED COMPLIANCE WITH NASDAQ LISTING RULE.

T2 Biosystems Expects Demand For T2SARS-COV-2 Test Upon Being Made Commercially Available For Clinical Use

May 22 (Reuters) - T2 Biosystems Inc <TTOO.O>::T2 BIOSYSTEMS - ANTICIPATES DEMAND FOR THE T2SARS-COV-2 TEST UPON BEING MADE COMMERCIALLY AVAILABLE FOR CLINICAL USE.T2 BIOSYSTEMS INC - CURRENTLY HAS RESOURCES TO MANUFACTURE UP TO 100,000 TESTS PER MONTH.T2 BIOSYSTEMS - SUBJECT TO SECURING ADDITIONAL NON-DILUTIVE FUNDING, ESTIMATES CO COULD POTENTIALLY RAMP TO ABOUT 1 MILLION TESTS PER MONTH.T2 BIOSYSTEMS INC - ANTICIPATES SHIPPING FIRST TESTS TO U.S. CUSTOMERS FOR CLINICAL USE AS EARLY AS END OF JUNE.

T2 Biosystems Q1 Loss Per Share $0.22

May 5 (Reuters) - T2 Biosystems Inc <TTOO.O>::T2 BIOSYSTEMS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.22.Q1 REVENUE $2.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $2.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.24 -- REFINITIV IBES DATA.REDUCED COST STRUCTURE AND A HEADCOUNT REDUCTION OF 22%.

T2 Biosystems Suspends Full Year 2020 Financial And Operational Guidance

March 24 (Reuters) - T2 Biosystems Inc <TTOO.O>::T2 BIOSYSTEMS ANNOUNCES PRELIMINARY FIRST QUARTER 2020 FINANCIAL RESULTS.SEES Q1 2020 REVENUE $2.2 MILLION TO $2.6 MILLION.SUSPENDED FULL YEAR 2020 FINANCIAL AND OPERATIONAL GUIDANCE.CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2020 ARE EXPECTED TO BE APPROXIMATELY $30.0 MILLION..

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up